TY - JOUR AU - Bradlow, Richard C. J. AU - Berk, Michael AU - Kalivas, Peter W. AU - Back, Sudie E. AU - Kanaan, Richard A. TI - The Potential of N-Acet(3)yl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders JF - CNS DRUGS J2 - CNS DRUGS VL - 36 PY - 2022 IS - 5 SP - 451 EP - 482 PG - 32 SN - 1172-7047 DO - 10.1007/s40263-022-00907-3 UR - https://m2.mtmt.hu/api/publication/32883771 ID - 32883771 AB - N-acetyl-L-cysteine (NAC) is a compound of increasing interest in the treatment of psychiatric disorders. Primarily through its antioxidant, anti-inflammatory, and glutamate modulation activity, NAC has been investigated in the treatment of neurodevelopmental disorders, schizophrenia spectrum disorders, bipolar-related disorders, depressive disorders, anxiety disorders, obsessive compulsive-related disorders, substance-use disorders, neurocognitive disorders, and chronic pain. Whilst there is ample preclinical evidence and theoretical justification for the use of NAC in the treatment of multiple psychiatric disorders, clinical trials in most disorders have yielded mixed results. However, most studies have been underpowered and perhaps too brief, with some evidence of benefit only after months of treatment with NAC. Currently NAC has the most evidence of having a beneficial effect as an adjuvant agent in the negative symptoms of schizophrenia, severe autism, depression, and obsessive compulsive and related disorders. Future research with well-powered studies that are of sufficient length will be critical to better understand the utility of NAC in the treatment of psychiatric disorders. LA - English DB - MTMT ER - TY - JOUR AU - Hans, D. AU - Rengel, A. AU - Hans, J. AU - Bassett, D. AU - Hood, S. TI - N-Acetylcysteine as a novel rapidly acting anti-suicidal agent: A pilot naturalistic study in the emergency setting JF - PLOS ONE J2 - PLOS ONE VL - 17 PY - 2022 IS - 1 January SN - 1932-6203 DO - 10.1371/journal.pone.0263149 UR - https://m2.mtmt.hu/api/publication/32683479 ID - 32683479 N1 - Export Date: 18 February 2022 CODEN: POLNC Correspondence Address: Hans, D.; School of Psychiatry and Clinical Neurosciences, Australia; email: davhans@gmail.com AB - Objective N-acetylcysteine has a demonstrated role as an adjunctive therapy in psychotic and affective disorders as a treatment to reduce symptoms of Bipolar Affective Disorder, Major Depressive Disorder and Schizophrenia. However, its potential as a rapidly acting anti-suicidal agent has not yet been assessed. This naturalistic study evaluates its effect in thirty patients presenting following intentional medication overdose. Methods Eighteen patients who ingested toxic doses of paracetamol received NAC whilst twelve other patients with other overdoses received standard supportive treatment in the emergency department setting. Symptoms were measured using the Montgomery-Asberg Depression Rating Scale and Clinical Global Impression scale at time of presentation, 24 hours, and seven days. Results Baseline characteristics between groups were similar. Both groups showed a significant reduction in suicidality, as measured by the suicide item of the MADRS, over time (p < 0.001). However, there was a greater reduction in suicidality in the 'NAC group' compared to the 'no-NAC group' one-week post presentation (p = 0.014). A greater proportion of the 'no-NAC group' still exhibited severe depressive symptoms (MADRS >32) compared to the 'NAC group' (p = 0.044). Conclusion This naturalistic study suggests NAC may have potential use as a rapidly acting treatment adjunct in major depressive disorder, warranting further investigation of its effects. Copyright: © 2022 Hans et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. LA - English DB - MTMT ER - TY - JOUR AU - Mardani, Nafiseh AU - Mozafarpoor, Samaneh AU - Goodarzi, Azadeh AU - Nikkhah, Farahnaz TI - A systematic review of N-acetylcysteine for treatment of acne vulgaris and acne-related associations and consequences: Focus on clinical studies JF - DERMATOLOGIC THERAPY J2 - DERMATOL THER VL - 34 PY - 2021 IS - 3 PG - 17 SN - 1396-0296 DO - 10.1111/dth.14915 UR - https://m2.mtmt.hu/api/publication/32303616 ID - 32303616 AB - Acne vulgaris is one of the most common dermatologic disorders affects people of all races and ethnicities and has many adverse effects on the quality of life. The increased bacterial resistance to antibiotics has reduced the effectiveness of treatment with these agents. There is an increasing focus on the involvement of oxidative stress in the pathophysiology of acne. This study investigates the effect of N-acetylcysteine (NAC) as an antioxidant in the treatment of acne vulgaris. This systematic review was conducted through a search in databases such as Science Direct, PubMed, Scielo, and Medline using keywords including acne vulgaris, anti and NAC, and all the keywords associated with each of the subtitles. The factors affecting the occurrence and expansion of acne include increased sebum synthesis, hyperkeratinization of pilosebaceous units, colonization with Propionibacterium acnes, and increased release of inflammatory mediators and ROS. Studies have shown that glutathione stimulation following the administration of NAC increases glutathione levels for the detoxification of oxygen-free radicals. Moreover, NAC prevents the synthesis and release of inflammatory cytokines such as TNF-alpha, IL-8, IL-6, MP9, and IL-1 beta and has shown antibacterial activities against important bacteria including E. coli, S. epidermidis, Pseudomonas, and Klebsiella. This medication has anti-proliferative effects and is also used for excoriation and PCOD. The results of the present study showed the beneficial effects of using NAC in patients with acne vulgaris in terms of the disease complications and comorbidities. Given its diverse functional mechanisms, this medication can be used to treat acne and its consequences. LA - English DB - MTMT ER - TY - JOUR AU - Ghaderi, Amir AU - Bussu, Anna AU - Tsang, Catherine AU - Jafarnejad, Sadegh TI - Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials JF - EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY J2 - EUR J CLIN PHARMACOL VL - 75 PY - 2019 IS - 3 SP - 289 EP - 301 PG - 13 SN - 0031-6970 DO - 10.1007/s00228-018-2595-1 UR - https://m2.mtmt.hu/api/publication/30651282 ID - 30651282 N1 - RETRACTED / VISSZAVONT AB - ObjectiveTo conduct a systematic review and meta-analysis of published randomised controlled trials on the efficacy of NAC supplementation on positive and negative syndrome scale in schizophrenia.MethodsA meta-analysis was conducted, and studies were identified by a search of electronic databases from inception to May 2018. Combined and stratified analyses were used.ResultsSeven trials were identified, and data from n=447 participants were included. Pooled analysis showed improvement of positive and negative syndrome scale following NAC treatment compared with placebo, for total (SMB=-0.96) [95% CI -1.69, -0.24; P=0.009], general (SMB=-1.04) [95% CI -1.80, -0.27; P=0.008] and negative (SMB=-0.73) [95% CI -1.29, -0.17; P=0.01] scores, respectively. Significant heterogeneity was found, and subgroup analysis showed significant reductions in studies with a treatment duration of 24weeks, with a considerable effect size on total, general, and negative scores (Total SMD=-0.83; General SMD=-0.67; Negative SMD=-1.09) following NAC.ConclusionsNAC improved all aspects of positive and negative syndrome scale in schizophrenic populations and may be more efficacious with treatment durations up to 24weeks. LA - English DB - MTMT ER - TY - JOUR AU - Moghadas, M. AU - Essa, M.M. AU - Ba-Omar, T. AU - Al-Shehi, A. AU - Qoronfeh, M.W. AU - Eltayeb, E.A. AU - Guillemin, G.J. AU - Manivasagam, T. AU - Justin-Thenmozhi, A. AU - Al-Bulushi, B.S. AU - Al-Adawi, S. AU - Edalatmanesh, M.A. TI - Antioxidant therapies in attention deficit hyperactivity disorder JF - FRONTIERS IN BIOSCIENCE-LANDMARK J2 - FRONT BIOSCI-LANDMARK VL - 24 PY - 2019 IS - 2 SP - 313 EP - 333 PG - 21 SN - 2768-6701 DO - 10.2741/4720 UR - https://m2.mtmt.hu/api/publication/30762602 ID - 30762602 N1 - Department of Biology, College of Science, Sultan Qaboos University, Muscat, Oman Department of Food Science and Nutrition, Ageing and Dementia Research Group, College of Agricultural and Marine Sciences, Sultan Qaboos University, Muscat, Oman Research and Policy Department, World Innovation Summit for Health (WISH), Qatar Foundation, P.O. Box 5825, Doha, Qatar Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia Department of Biochemistry, Faculty of Science, Annamalai University, Tamilnadu, India Department of Behavioral Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman Department of Biology, College of Sciences, Shiraz Branch, Islamic Azad University, Shiraz, Iran Export Date: 11 August 2019 Correspondence Address: Essa, M.M.; Department of Food Science and Nutrition, Ageing and Dementia Research Group, College of Agricultural and Marine Sciences, Sultan Qaboos UniversityOman; email: drmdessa@gmail.com Chemicals/CAS: ascorbic acid, 134-03-2, 15421-15-5, 50-81-7; glutathione, 70-18-8; Antioxidants; Ascorbic Acid; Biological Products; Glutathione Funding details: Buchtel College of Arts and Sciences Funding details: Qatar Foundation, 4Department Funding details: Macquarie University, 6Department Funding details: College of Medicine and Health Sciences, University of Gondar Funding details: Islamic Azad University Funding details: Sultan Qaboos University Funding details: College of Agricultural and Life Sciences Funding text 1: 1Department of Biology, College of Science, Sultan Qaboos University, Muscat, Oman, 2Department of Food Science and Nutrition, Ageing and Dementia Research Group, College of Agricultural and Marine Sciences, Sultan Qaboos University, Muscat, Oman, 3Research and Policy Department, World Innovation Summit for Health (WISH), Qatar Foundation, P.O. Box 5825, Doha, Qatar, 4Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia, 5Department of Biochemistry, Faculty of Science, Annamalai University, Tamilnadu, India, 6Department of Behavioral Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman, 7Department of Biology, College of Sciences, Shiraz Branch, Islamic Azad University, Shiraz, Iran AB - Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder among children and adults. Impulsivity, inattention, and hyperactivity are hallmark of ADHD. While ADHD is not on the autism spectrum, they are related in several ways as they have some overlapping symptoms. The pathogenesis of ADHD has so far remained enigmatic, however, there is some evidence suggesting critical association among ADHD and the level of oxidative stress which trigger cell membrane damage, changes in inner structure and function of proteins, as well as structural damage to DNA which eventually culminate into development of ADHD. Although stimulants as well as some classes of non-stimulants are used to ameliorate symptom of ADHD, various adverse effects have been associated with such compounds. To date, treatment of ADHD is done with a combination of medications, behavior modifications, psycho-education, family therapy and life-style changes. The American Academy of Pediatrics officially promote stimulant medications and/or behavior therapy as 'first line of therapy'. In addition to the presently therapeutic armamentarium, evidences are emerging on relevancy of natural products. There has been an interest on the therapeutic role of antioxidants in the treatment of ADHD. The present review aims to highlight the beneficiary role played by different antioxidants in mitigating the symptoms of ADHD. © 2019 Frontiers in Bioscience. All Rights Reserved. LA - English DB - MTMT ER - TY - JOUR AU - Adil, Mohammad AU - Amin, Syed Suhail AU - Mohtashim, Mohd TI - N-acetylcysteine in dermatology JF - INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY J2 - INDIAN J DERMATOL VE VL - 84 PY - 2018 IS - 6 SP - 652 EP - 659 PG - 8 SN - 0378-6323 DO - 10.4103/ijdvl.IJDVL_33_18 UR - https://m2.mtmt.hu/api/publication/30895641 ID - 30895641 AB - N-acetylcysteine is a mucolytic drug which is commonly used as an antidote for acetaminophen toxicity. It is a thiol compound, which acts as a donor of cysteine, leading to replenishment of glutathione and thus acts as an antioxidant. It also has anti-inflammatory effects, alters the levels of neurotransmitters, inhibits proliferation of fibroblasts and keratinocytes and causes vasodilatation. Due to these actions, n-acetylcysteine has found use in several dermatologic conditions in systemic and topical form. The drug has been used as an adjuvant in the management of conditions such as toxic epidermal necrolysis, drug hypersensitivity syndrome, trichotillomania, skin picking disorders and onychotillomania, ichthyoses, contact dermatitis, atopic dermatitis, melasma, pseudoporphyria, connective tissue diseases, wound healing and alopecia. It also has a role in protection from radiation-induced skin damage including photo-ageing, photocarcinogenesis and radiation dermatitis. Most indications in dermatology are supported by case reports, small case series and small trials. Higher quality of evidence is needed for its wider use. The drug is cheap and is generally safe with few adverse effects. Thus a greater role is possible for use of n-acetylcysteine in various skin conditions. This review explores the various uses of n-acetylcysteine in the field of dermatology, the evidence supporting the same, the possible mechanisms of action and the adverse effects of the drug. LA - English DB - MTMT ER - TY - JOUR AU - Bernhardt, Liegelin Kavitha AU - Bairy, K Lakshminarayana AU - Madhyastha, Sampath TI - Neuroprotective Role of N-acetylcysteine against Learning Deficits and Altered Brain Neurotransmitters in Rat Pups Subjected to Prenatal Stress JF - BRAIN SCIENCES J2 - BRAIN SCI VL - 8 PY - 2018 IS - 7 PG - 13 SN - 2076-3425 DO - 10.3390/brainsci8070120 UR - https://m2.mtmt.hu/api/publication/27553146 ID - 27553146 LA - English DB - MTMT ER - TY - JOUR AU - Sepehrmanesh, Zahra AU - Heidary, Mahsa AU - Akasheh, Negar AU - Akbari, Hossein AU - Heidary, Mahshid TI - Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial JF - PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY J2 - PROG NEURO-PSYCHOPHARMACOL BIOL PSYCHIATR VL - 82 PY - 2018 SP - 289 EP - 296 PG - 8 SN - 0278-5846 DO - 10.1016/j.pnpbp.2017.11.001 UR - https://m2.mtmt.hu/api/publication/27341383 ID - 27341383 N1 - Department of psychiatry, School of Medicine, Kashan University of Medical Science, Kashan, Iran School of Medicine, Qazvin University of Medical Science, Qazvin, Iran Department of Public Health, Kashan University Of Medical Sciences, kashan, Iran Department of Clinical Psychology, Qom Islamic Azad University, Qom, Iran Export Date: 16 July 2019 CODEN: PNPPD Funding Agency and Grant Number: Kashan University of Medical Sciences Funding text: The study was supported by funding from research and technical council of Kashan University of Medical Sciences1200 $ and was registered in Iranian Registry of Clinical Trials (Registration number: IRCT: 2015080223463N1 www.irct.ir). The authors would like to thank the Clinical Research development of Kargarnejad hospital and the patients who participated in this study. Export Date: 20 October 2020 CODEN: PNPPD LA - English DB - MTMT ER - TY - JOUR AU - Aguiar, Gean Pablo S AU - Marcon, Matheus AU - Mocelin, Ricieri AU - Herrmann, Ana P AU - Chaves, Lorenzo M P C AU - Piato, Angelo L AU - Lanza, Marcelo AU - Vladimir, Oliveira J TI - Micronization of N-acetylcysteine by supercritical fluid: Evaluation of in vitro and in vivo biological activity JF - JOURNAL OF SUPERCRITICAL FLUIDS J2 - J SUPERCRIT FLUID VL - 130 PY - 2017 SP - 282 EP - 291 PG - 10 SN - 0896-8446 DO - 10.1016/j.supflu.2017.06.010 UR - https://m2.mtmt.hu/api/publication/27071387 ID - 27071387 LA - English DB - MTMT ER - TY - JOUR AU - Arturo, Martinez-Banaclocha Marcos TI - Cysteinet Dysregulation in Muscular Dystrophies: A Pathogenic Network Susceptible to Therapy JF - CURRENT MEDICINAL CHEMISTRY J2 - CURR MED CHEM VL - 24 PY - 2017 IS - 3 SP - 312 EP - 330 PG - 19 SN - 0929-8673 DO - 10.2174/0929867323666161129124549 UR - https://m2.mtmt.hu/api/publication/26554750 ID - 26554750 N1 - Cited By :2 Export Date: 14 June 2023 CODEN: CMCHE Correspondence Address: Arturo Martinez-Banaclocha, M.; Pathology Service, Spain; email: martinez_marben@gva.es Chemicals/CAS: acetylcysteine, 616-91-1; cysteine, 4371-52-2, 52-89-1, 52-90-4; glutathione, 70-18-8; Acetylcysteine; Cysteine LA - English DB - MTMT ER - TY - JOUR AU - Al-Samhari, Marwa M AU - Al-Rasheed, Nouf M AU - Al-Rejaie, Salim AU - Al-Rasheed, Nawal M AU - Hasan, Iman H AU - Mahmoud, Ayman M AU - Dzimiri, Nduna TI - Possible involvement of the JAK/STAT signaling pathway in N-acetylcysteine-mediated antidepressant-like effects JF - EXPERIMENTAL BIOLOGY AND MEDICINE J2 - EXP BIOL MED VL - 241 PY - 2016 IS - 5 SP - 509 EP - 518 PG - 10 SN - 1535-3702 DO - 10.1177/1535370215619707 UR - https://m2.mtmt.hu/api/publication/25773845 ID - 25773845 LA - English DB - MTMT ER - TY - JOUR AU - Beard, Emma AU - Shahab, Lion AU - Cummings, Damian M AU - Michie, Susan AU - West, Robert TI - New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline? JF - CNS DRUGS J2 - CNS DRUGS VL - 30 PY - 2016 IS - 10 SP - 951 EP - 983 PG - 33 SN - 1172-7047 DO - 10.1007/s40263-016-0362-3 UR - https://m2.mtmt.hu/api/publication/26206036 ID - 26206036 LA - English DB - MTMT ER - TY - JOUR AU - Salum, Cristiane AU - Schmidt, Fanny AU - Michel, Patrick P AU - Del-Bel, Elaine AU - Raisman-Vozari, Rita TI - Signaling Mechanisms in the Nitric Oxide Donor- and Amphetamine-Induced Dopamine Release in Mesencephalic Primary Cultured Neurons JF - NEUROTOXICITY RESEARCH J2 - NEUROTOX RES VL - 29 PY - 2016 IS - 1 SP - 92 EP - 104 PG - 13 SN - 1029-8428 DO - 10.1007/s12640-015-9562-8 UR - https://m2.mtmt.hu/api/publication/25773846 ID - 25773846 N1 - Cited By :2 Export Date: 26 April 2021 CODEN: NURRF Correspondence Address: Salum, C.; Centro de Matemática, Rua Arcturus, 3 – Jardim Antares, Brazil; email: cristiane.salum@ufabc.edu.br Chemicals/CAS: 1h 1,2,4 oxadiazolo[4,3 a]quinoxalin 1 one, 41443-28-1; acetylcysteine, 616-91-1; amphetamine, 1200-47-1, 139-10-6, 156-34-3, 2706-50-5, 300-62-9, 51-62-7, 60-13-9, 60-15-1; dizocilpine, 77086-21-6; nifedipine, 21829-25-4; dizocilpine maleate, 77086-22-7; dopamine, 51-61-6, 62-31-7; nitrite, 14797-65-0; Amphetamine; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine; Neuroprotective Agents; Nifedipine; Nitric Oxide Donors; Nitrites; Nitroso Compounds; NOC 12 Funding text 1: This work was supported by a grant from Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior and Comit? Fran?ais d' Evaluation de la Cooperation Universitaire avec le Br?sil (CAPES/COFECUB n? 491/05?Brazil/France). LA - English DB - MTMT ER - TY - JOUR AU - Jahanshahi, B AU - Raoof, JB AU - Amiri-Aref, M AU - Ojani, R TI - A voltammetric sensor based on modified multi-walled carbon nanotubes for N-acetyl-L-cysteine determination in the presence of tryptophan using 4-chlorocatechol as a homogenous electrochemical catalyst JF - JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY J2 - J NANOSCI NANOTECHNO VL - 15 PY - 2015 IS - 5 SP - 3429 EP - 3436 PG - 8 SN - 1533-4880 DO - 10.1166/jnn.2015.10212 UR - https://m2.mtmt.hu/api/publication/24453694 ID - 24453694 LA - English DB - MTMT ER - TY - JOUR AU - Taracha, E AU - Kaniuga, E AU - Chrapusta, S J AU - Boguszewski, P M AU - Lehner, M AU - Krzaścik, P AU - Płaźnik, A TI - N-acetyl cysteine does not modify the sensitization of the rewarding effect of amphetamine as assessed with frequency-modulated 50-kHz vocalization in the rat JF - BEHAVIOURAL BRAIN RESEARCH J2 - BEHAV BRAIN RES VL - 280 PY - 2015 SP - 141 EP - 148 PG - 8 SN - 0166-4328 DO - 10.1016/j.bbr.2014.12.005 UR - https://m2.mtmt.hu/api/publication/24409033 ID - 24409033 LA - English DB - MTMT ER - TY - JOUR AU - Bavarsad, Shahripour R AU - Harrigan, M R AU - Alexandrov, A V TI - N-acetylcysteine (NAC) in neurological disorders: Mechanisms of action and therapeutic opportunities JF - BRAIN AND BEHAVIOR J2 - BRAIN BEHAV VL - 4 PY - 2014 IS - 2 SP - 108 EP - 122 PG - 15 SN - 2162-3279 DO - 10.1002/brb3.208 UR - https://m2.mtmt.hu/api/publication/24409031 ID - 24409031 LA - English DB - MTMT ER - TY - CHAP AU - Giselli, Scaini AU - Gabriela, C Jeremias AU - Camila, B Furlanetto AU - Diogo, Dominguini AU - Clarissa, M Comim AU - João, Quevedo AU - Patrícia, F Schuck AU - Gustavo, C Ferreira AU - Emilio, L Streck ED - Zschocke, Johannes ED - Gibson, K. Michael ED - Brown, Garry ED - Morava, Eva ED - Peters, Verena TI - Behavioral Responses in Rats Submitted to Chronic Administration of Branched-Chain Amino Acids T2 - JIMD Reports - Case and Research Reports, Volume 13 PB - Springer Netherlands CY - Berlin SN - 9783642541490 T3 - JIMD Reports, ISSN 2192-8304 ; 13. PY - 2014 SP - 159 EP - 167 PG - 9 DO - 10.1007/8904_2013_274 UR - https://m2.mtmt.hu/api/publication/24409133 ID - 24409133 LA - English DB - MTMT ER - TY - JOUR AU - Berk, M AU - Malhi, GS AU - Gray, LJ AU - Dean, OM TI - The promise of N-acetylcysteine in neuropsychiatry JF - TRENDS IN PHARMACOLOGICAL SCIENCES J2 - TRENDS PHARMACOL SCI VL - 34 PY - 2013 IS - 3 SP - 167 EP - 177 PG - 11 SN - 0165-6147 DO - 10.1016/j.tips.2013.01.001 UR - https://m2.mtmt.hu/api/publication/23606782 ID - 23606782 N1 - Funding Agency and Grant Number: AstraZenecaAstraZeneca; Eli LillyEli Lilly; Organon; PfizerPfizer; ServierServier; WyethWyeth; Medical Benefits Fund of Australia; Bristol-Myers SquibbBristol-Myers Squibb; GlaxoSmithKlineGlaxoSmithKline; NovartisNovartis; Mayne Pharma; Rebecca L. Cooper Medical Research Foundation; Brain and Behaviour Foundation; Simons Autism Foundation; Stanley Medical Research Institute; LillyEli Lilly; National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; Society for Bipolar and Depressive Disorders (ASBDD)/Servier grant Funding text: G.S.M. has received research support from AstraZeneca, Eli Lilly, Organon, Pfizer, Servier, and Wyeth; has been a speaker for AstraZeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer, Ranbaxy, Servier, and Wyeth; and has been a consultant for AstraZeneca, Eli Lilly, Janssen Cilag, Lundbeck, and Servier. M.B. has received research support from the Medical Benefits Fund of Australia, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, and Servier; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithEline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay, and Wyeth; and has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, and Servier. M.B. is a co-inventor on two provisional patents regarding the use of NAC and related compounds for psychiatric indications, assigned to the Mental Health Research Institute. L.J.G. has received grant support from the Rebecca L. Cooper Medical Research Foundation. O.M.D. has received grant support from the Brain and Behaviour Foundation, the Simons Autism Foundation, the Stanley Medical Research Institute, Lilly, National Health and Medical Research Council (NHMRC), and an Society for Bipolar and Depressive Disorders (ASBDD)/Servier grant. Export Date: 20 October 2020 CODEN: TPHSD LA - English DB - MTMT ER - TY - JOUR AU - Pásztiné Gere, Erzsébet AU - Jakus, Judit TI - Protein phosphatases but not reactive oxygen species play functional role in acute amphetamine-mediated dopamine release JF - CELL BIOCHEMISTRY AND BIOPHYSICS J2 - CELL BIOCHEM BIOPHYS VL - 66 PY - 2013 IS - 3 SP - 831 EP - 841 PG - 11 SN - 1085-9195 DO - 10.1007/s12013-013-9608-6 UR - https://m2.mtmt.hu/api/publication/2285675 ID - 2285675 LA - English DB - MTMT ER - TY - JOUR AU - Farokhnia, M AU - Azarkolah, A AU - Adinehfar, F AU - Khodaie-Ardakani, MR AU - Hosseini, SMR AU - Yekehtaz, H AU - Tabrizi, M AU - Rezaei, F AU - Salehi, B AU - Sadeghi, SMH AU - Moghadam, M AU - Gharibi, F AU - Mirshafiee, O AU - Akhondzadeh, S TI - N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study JF - CLINICAL NEUROPHARMACOLOGY J2 - CLIN NEUROPHARMACOL VL - 36 PY - 2013 IS - 6 SP - 185 EP - 192 PG - 8 SN - 0362-5664 DO - 10.1097/WNF.0000000000000001 UR - https://m2.mtmt.hu/api/publication/23754943 ID - 23754943 N1 - Funding Agency and Grant Number: Tehran University of Medical SciencesTehran University of Medical Sciences Funding text: S.A. has received a grant from Tehran University of Medical Sciences. The funding organization had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript and the decision to submit the paper for publication. Export Date: 20 October 2020 CODEN: CLNED LA - English DB - MTMT ER - TY - JOUR AU - Samuni, Y AU - Goldstein, S AU - Dean, OM AU - Berk, M TI - The chemistry and biological activities of N-acetylcysteine JF - BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS J2 - BBA-GEN SUBJECTS VL - 1830 PY - 2013 IS - 8 SP - 4117 EP - 4129 PG - 13 SN - 0304-4165 DO - 10.1016/j.bbagen.2013.04.016 UR - https://m2.mtmt.hu/api/publication/24489451 ID - 24489451 N1 - Megjegyzés-23254352 N1 : Chemicals/CASacetylcysteine, 616-91-1; doxorubicin, 23214-92-8, 25316-40-9; glutathione, 70-18-8; glyceryl trinitrate, 55-63-0; hydrogen peroxide, 7722-84-1; paracetamol, 103-90-2; paraquat, 1910-42-5, 3240-78-6, 4685-14-7; streptokinase, 9002-01-1; superoxide, 11062-77-4; thiol derivative, 13940-21-1 LA - English DB - MTMT ER - TY - JOUR AU - Maes, M AU - Fišar, Z AU - Medina, M AU - Scapagnini, G AU - Nowak, G AU - Berk, M TI - New drug targets in depression: Inflammatory, cell-mediate immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. and new drug candidates-Nrf2 activators and GSK-3 inhibitors JF - INFLAMMOPHARMACOLOGY J2 - INFLAMMOPHARMACOLOGY VL - 20 PY - 2012 IS - 3 SP - 127 EP - 150 PG - 24 SN - 0925-4692 DO - 10.1007/s10787-011-0111-7 UR - https://m2.mtmt.hu/api/publication/23689059 ID - 23689059 N1 - Maes Clinics at TRIA, 998 Rimklongsamsen Road, Bangkok 10310, Thailand Department of Psychiatry, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic Noscira, Tres Cantos, Spain Department of Health Sciences, University of Molise, Campobasso, Italy Department of Pharmacobiology, Jagiellonian University Medical College, Institute of Pharmacology PAS, Krakow, Poland Department of Clinical and Biomedical Sciences, University of Melbourne, Melbourne, VIC, Australia Orygen Research Centre, Centre for Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia Mental Health Research Institute, Melbourne, Australia Cited By :230 Export Date: 1 September 2021 CODEN: IAOAE Correspondence Address: Maes, M.; Maes Clinics at TRIA, 998 Rimklongsamsen Road, Bangkok 10310, Thailand; email: dr.michaelmaes@hotmail.com Chemicals/CAS: acetylcysteine, 616-91-1; acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; agomelatine, 138112-76-2; celecoxib, 169590-42-5; curcumin, 458-37-7; etanercept, 185243-69-0, 200013-86-1; fenfluramine, 404-82-0, 458-24-2; imipramine, 113-52-0, 50-49-7; ketamine, 1867-66-9, 6740-88-1, 81771-21-3; liquiritin, 551-15-5; lithium, 7439-93-2; losmapimod, 585543-15-3; minocycline, 10118-90-8, 11006-27-2, 13614-98-7; resveratrol, 501-36-0; saponin, 8047-15-2; sertraline, 79617-96-2; ubidecarenone, 303-98-0; valproic acid, 1069-66-5, 99-66-1; zinc, 14378-32-6, 7440-66-6; Antioxidants; Glycogen Synthase Kinase 3, 2.7.11.26; Inflammation Mediators; NF-E2-Related Factor 2; NFE2L2 protein, human Tradenames: gw 856553 LA - English DB - MTMT ER - TY - JOUR AU - Smaga, I AU - Pomierny, B AU - Krzyzanowska, W AU - Pomierny-Chamiolo, L AU - Miszkiel, J AU - Niedzielska, E AU - Ogorka, A AU - Filip, M TI - N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: Behavioral and biochemical analyses in rats JF - PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY J2 - PROG NEURO-PSYCHOPHARMACOL BIOL PSYCHIATR VL - 39 PY - 2012 IS - 2 SP - 280 EP - 287 PG - 8 SN - 0278-5846 DO - 10.1016/j.pnpbp.2012.06.018 UR - https://m2.mtmt.hu/api/publication/22847161 ID - 22847161 LA - English DB - MTMT ER - TY - JOUR AU - Olivia, Dean AU - Frank, Giorlando AU - Michael, Berk TI - N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action JF - JOURNAL OF PSYCHIATRY & NEUROSCIENCE J2 - J PSYCHIATR NEUROSCI VL - 36 PY - 2011 IS - 2 SP - 78 EP - 86 PG - 9 SN - 1180-4882 DO - 10.1503/jpn.100057 UR - https://m2.mtmt.hu/api/publication/21689441 ID - 21689441 LA - English DB - MTMT ER -